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Expression analysis of beta-secretase 1 (BACE1) enzyme in 
peripheral blood of patients with Alzheimer's disease 
 
 
Abstract 
Background: Recent evidence has indicated that beta-secretase 1 (BACE1) is involved in 
the production of amyloid beta (Aβ) in patients affected with Alzheimer’s disease (AD). 
Therefore; the purpose of this study was to measure mRNA and plasma levels of BACE1 
in AD patients, as an early diagnosis biomarker for such individuals. 
Methods: A total number of thirty AD patients and thirty normal subjects as controls were 
recriuted in the present study. Plasma levels of BACE1 were then examined via enzyme-
linked immunosorbent assay (ELISA) and also mRNA expression of BACE1 in total blood 
was measured using real-time PCR technique. 
Results: The findings revealed a significant difference in gene expression of BACE1 in the 
peripheral blood of AD patients compared with that in controls (p<0.0001). Additionally, 
elevated plasma levels of BACE1 were found in AD patients compared with those in 
normal subjects (p<0.01). Statistical analyses also demonstrated no correlation between 
expression (mRNA and protein) of BACE1 in both AD patients and controls and age or the 
results of Mini-Mental State Examination (MMSE) scale (p>0.05). 
Conclusion: Given the importance of early diagnosis of AD patients, it was suggested that 
the measurement of plasma levels and also mRNA expression of BACE1 might be a 
valuable blood-based biomarker used in preference to other invasive diagnostic methods 
such as cerebrospinal fluid (CSF) analysis. 
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Alzheimer’s disease (AD) is known as a progressive neurodegenerative disease, and 
evidence has indicated that it is the most dominant form of dementia in the elderly (1). 
Moreover, deposits of extracellular Aβ protein and intracellular neurofibrillary tangles 
(NFTs) are involved in the pathophysiology of AD through the formation of senile plaques 
(2). Previous human and experimental studies have also revealed that activity and protein 
levels of beta-secretase 1 (BACE1) can have a remarkable elevation in the brain tissue and 
cerebrospinal fluid (CSF) of patients suffering from AD and a positive correlation has been 
even reported between Aβ protein load and increased levels of BACE1 (3, 4). However, 
few studies had found that the source of BACE1 could be non-neuronal cells (5). Increased 
activity of the enzyme and some of the Aβ protein soluble secreted segments in the plasma 
of AD patients had been also observed (6). Currently; imaging techniques such as 
magnetic resonance imaging (MRI), positron-emission tomography (PET) or analysis of 
CSF are utilized for the early diagnosis of AD  despite the fact that each method is 
encountering problems such as high costs, inaccessibility at all locations, and invasiveness 
(7). 
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Furthermore; it should be noted that high potential 
biomarkers, including blood-based biomarkers, MRI 
biomarkers, PET biomarkers, as well as CSF biomarkers can 
play an important role in early prediction, screening, and 
diagnosis of AD patients (8). In this regard, blood-based 
biomarkers have become especially of utmost significance 
thanks to their better patient acceptance, cost-effectiveness, 
and less invasive sampling methods (8). However, the use of 
these biomarkers in clinical practice has not become routine 
and there are numerous obscurities in this domain. 
Therefore, the purpose of this study was to measure mRNA 
and plasma levels of BACE1 in the peripheral blood of AD 
patients in comparison with normal subjects considering the 
evaluation of a novel and profitable blood-based biomarker 
for the early diagnosis of AD patients. In this study, all of the 
AD patients were CDR1 and lower grade. Additionally, the 
enzyme-linked immunosorbent assay (ELISA) kit which was 
used in this study had a better sensitivity compared to 
previous studies. 
 
 
Methods 
Subjects: In this study, a total number of thirty AD patients 
diagnosed based on diagnostic criteria for AD (National 
Institute of Neurological Disorders and Stroke-Alzheimer 
Disease and Related Disorders Association) (9) along with 
thirty healthy controls were recruited. The AD patients and 
the control subjects were also matched in terms of variables 
such as age and gender. Moreover; subjects with 
schizophrenia, major depressive disorder, mental retardation, 
substance-related disorder; bipolar disorder, hydrocephalus, 
cerebrovascular disease, clinically considerable variations in 
vitamin B12, cranial trauma, visual and auditory disorders 
(non-correctable), non-compensated hypertension, 
hypothyroidism, syphilis, diabetes, neoplasia; as well as 
cardiac, pulmonary, hepatic, and renal diseases were 
excluded from this study (7). The Mini-Mental State 
Examination (MMSE)  was used as a score for the diagnosis 
of dementia and also clinical dementia rating (CDR) was 
applied as the index for the severity of AD symptoms in the 
patients. These individuals demonstrated cerebral atrophy in 
cranial MRI or CT scan and no cerebrovascular lesions. It 
should be noted that CSF was not measured for the diagnosis 
of the AD patients. All these individuals were also 
undergoing treatments with one of the cholinesterase 
inhibitors such as donepezil, rivastigmine, galantamine, or 
N-methyl D-aspartate receptor antagonist (memantine). This 
study was approved by the Ethics Committee of Rafsanjan 
University of Medical Sciences, Iran. In addition, informed 
consent was obtained from all study subjects or their families 
in accordance with the Declaration of Helsinki. 
BACE1 Immunoassay: The plasma levels of BACE1 were 
measured using an immunoassay kit (CUSABIO, USA). The 
measurement procedure was also fulfilled according to the 
guidelines described in user’s instructions provided by the 
manufacturer. As observed in the kit’s instructions, the 
sensitivity of the kit was 0.78 pg/mL. It should be noted that 
the data were only used when inter- and intra-assays 
produced scores of CV<15% and CV<5%, respectively. 
Extraction of RNA, Reverse Transcription, and 
Quantitative Real-Time PCR: The peripheral blood 
leukocytes were isolated from collected whole blood and the 
total mRNA content was isolated from the peripheral blood 
leukocytes using an mRNA extraction kit (Cat.# 9767, 
Takara, Kyoto, Japan). Briefly; lysis suspension leukocytes 
were centrifuged at 8,000 Xg at 4
°
C for 2 minutes, then the 
supernatant was discarded and the cell pellet was re-
suspended with 1X PBS, and centrifuged at 8,000 Xg at 4
°
C 
for 2 minutes again. An appropriate volume of the RL buffer 
was also added to the cell pellets and the cell lysates were 
incubated at room temperature for 2 minutes. Next, the 
lysates were applied to gDNA Eraser Spin Column in the 
collection tube and subsequently centrifuged at 12,000 rpm 
for 1 minute. gDNA Eraser Spin Column was also discarded 
and an equal volume of 70% ethanol was added to the flow-
through in the 2 ml collection tube and mixed thoroughly by 
pipetting it up and down. Furthermore, the mixture was 
applied to RNA Spin Column in 2-ml collection tube and 
centrifuged at 12,000 rpm for 1 minute. The flow-through 
was similarly discarded and 500 μl Buffer RWA was added 
to RNA Spin Column and subsequently centrifuged at 
12,000 rpm for 30 seconds and the flow-through was 
discarded (this step was repeated). Finally, 350 μl of RWB 
was added to the RNA Spin Column and centrifuged at 
12,000 rpm for 30 seconds. 
The cDNA was generated from the yielded total mRNA, 
employing PrimeScript™ II 1st strand cDNA Synthesis Kit 
(TaKaRa Bio, Shiga, Japan). The RT-PCR was subsequently 
performed in a 20 μL solution containing 10 μL SYBR® 
Premix Ex Taq TM (Takara, Japan), 0.4 μL ROX, 1.5 μL 
cDNA, and 0.5 μM of each primer, specific for BACE1 and 
β-actin and up to 20 μL nuclease-free water. The related 
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sequences for primers of the reference and target genes were 
presented in Table 1. Each separate RT-PCR assay was also 
completed in triplicate using a thermal cycler ABI Step One 
Plus® system (Applied Biosystems™, USA). As well, the 
actin-β was considered as a house-keeping gene (reference 
gene) aimed at normalization of the amplified signals of the 
BACE1 gene. Additionally, the relative BACE1 levels were 
calculated by 2
-∆∆Ct
 wherein ∆Ct = Ct (BACE1)-Ct (Actin-β) 
and ∆∆Ct = ∆Ct (peripheral blood leukocytes of AD 
patients)-∆Ct (peripheral blood leukocytes of normal 
subjects) (10).  
The SPSS stastistics software (Version 18) was used for 
the statistical analysis of the data. In this resepct, Student’s t-
test and Mann-Whitney U test were applied for normally and 
non-normally distributed data since continuous variables 
were compared. As well, categorical data were compared 
through chi-square test. To calculate the correlation 
coefficient between the scales, Pearson’s correlation 
coefficient and Spearman’s rank correlation coefficient were 
used for normally and non-normally distributed data; 
resepctively. Differences were also considered significant, 
whereby the p-value was less than 0.05. 
 
Table 1. Demonstrates the sequences of primers used in the study. 
 
Gene Forward Reverse Ta Product length 
Actin β GCGCGGCTACAGCTTCA CTTAATGTCACGCACGATTTCC 58 55 bp 
BACE1 GCCATCTGCGCCCTCTT AGCGCCACTGACACACCAT 58 55 bp 
Ta: annealing temperature           ; bp: base per 
 
Results 
Demographic and Clinical Characteristics: A total number 
of thirty patients affected with AD (12 women and 18 men) 
and thirty healthy subjects (10 women and 20 men) were 
recruited in this study. The demographic and the clinical 
characteristics of these patients were illustrated in Table 2. It 
should be noted that there was no significant difference 
between patients and healthy subjects in terms of age 
(p>0.05) and gender (p>0.05) (Table 2).  
 
Table 2. Clinical characteristics of AD patients and 
normal subjects 
Gender Male 18 20 NS 
Female 12 10 
       Age (years) 71.9±9.3 56.2±11.8 NS 
Educational 
background 
Illiteracy 25 (83% ) 20 (67% ) NS 
literacy 5 (17%) 10 (33% ) 
MMSE 14.10±6.8 29.87±5.4 <0.05 
Plasma levels of BACE1 
(pg/mL) 
27±7.4 8±2.6 <0.01 
NS: non-significant (>0.05) 
 
Plasma Level of BACE1: The results of this study showed a 
significant difference between the plasma levels of BACE1 
in patients with AD (27±7.4 pg/mL) compared with those in 
healthy controls (8±2.6 pg/mL) (p<0.01). Statistical analysis 
also revealed no correlation between the expression (mRNA  
 
 
and protein) of BACE1 in both AD patients and controls and 
age or MMSE scale (p>0.05). 
BACE1 Gene Expression (RT-PCR): The results of RT-
PCR analysis indicated a significant change in the gene 
expression of BACE1 using peripheral leukocytes on mRNA 
levels in AD patients compared with those in normal 
subjects (p<0.0001) (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1. Demonstrates alteration in mRNA level of BACE1 
in the peripheral blood of AD patients and normal 
subjects. Data are presented as mean ± SD, *= significant 
(P> 0.05). 
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Discussion 
In this study, the plasma levels of BACE1 in AD patients 
was examined and then the results were compared with those 
in healthy subjects. The findings of the present study also 
showed a significant change in the gene expression of 
BACE1 in peripheral blood and plasma levels of BACE1 
between AD patients and healthy controls. Furthermore, data 
analysis revealed no correlation between serum levels of 
BACE1 and clinical symptoms and AD severity.  
Evidence had also shown that amyloid precursor protein 
(APP) and its proteolysis via β- and γ-secretase enzymes 
were responsible for amyloidogenesis and generation of Aβ 
(11). In addition, previous studies had reported that BACE1 
was an important β-secretase (12) and animal-based studies 
had suggested that BACE1 as a major β-secretase, BACE2, 
and cathepsins might be involved in the formation of 
amyloid plaques (13, 14). In addition to the brain, the 
interesting point was that BACE1 could be found in other 
tissues of the body (15).  
To find about the various interactions between soluble 
blood proteins and Aβ, measurement of Aβ plasma levels 
had not been able to provide a profitable diagnostic marker 
for AD patients (16). Moreover, the plasma levels of Aβ had 
demonstrated no significant alteration in AD patinets 
compared with normal subjects (17). Measurment of BACE1 
levels in CSF of AD patients had also revealed the 
possibility of determining the levels of this enzyme in the 
blood and its compartments (18). Hence, given the few 
studies conducted on BACE1 measurements in the 
peripheral blood of AD patients, finding the answer to the 
question of whether the prepheral blood expression of the 
BACE1 could be used as a suitable early diagnostic 
biomarker could be worthwhile. 
In this respect Wu et al. reported a remarkable increasing 
trend in the activity BACE1 in the plasma of AD patients 
compared with that in normal subjects (6). Furthermore, 
findings by Manzine et al. highlighted a considerable 
elevation in the plasma levels of BACE1 in AD patients 
compared with those in non-AD controls (7). These results 
were consistent with the findings in the present study, except 
that in the investigation by Wu et al. in which BACE1 
activity was assessed, although the given parameters were 
closely related in most cases. The results of another study 
also stated that BACE1 enzyme activity was significantly 
elevated in the CSF of early-stage AD patients (19). In the 
present study, all of the AD patients were selected from the 
CDR stage one or lower and the sample size (n=30) and 
ELISA kits’ sensitivity (0.78 pg/mL) was improved 
compared with Manzine’s study (CDR1 patients=7 and 
ELISA kits’ sensitivity=1.0 pg/mL). The expression of 
BACE1 in peripheral blood mononuclear cell (PBMC) had 
been the subject of a few investigations and the relevant 
reports had shown lower amounts of BACE1 mRNA in 
PBMC compared with those in the brain (20). Contrary to 
the results of this study, Manzine et al. inferred that there 
was no significant change in the mRNA level of BACE1 in 
the peripheral blood of AD patients compared with that in 
normal subjects (7). Recently, in line with the findings of the 
present study, Feng et al. have reported that the plasma long 
non-coding RNA (LncRNA) BACE1 level of patients 
affected with AD was significantly higher than that of 
healthy controls (21). The discrepancies in the mentioned 
investigations might be due to differences in their 
methodologies; so, the type of biologic specimen, 
techniques, kits, sample size, and demographic 
characteristics of subjects, adminstered drugs (type and 
dose), as well as severity of the disease could have affected 
the outcomes.  
Considering all the variations influencing blood BACE1 
levels and activity, it could be concluded that mRNA and 
protein levels of BACE1 might be an early blood-based 
diagnostic tool for AD patients. Nonetheless, further studies 
with larger sample size and different methods such as 
western blotting or immunohistochemistry on brain tissue 
samples in transgenic mouse model of AD as well as 
measurement and comparison of the levels of BACE1 in 
CSF, plasma, and PBMCs of AD patients were needed to 
confirm the role of this enzyme in the patogenesis of AD. In 
this way, the potential of BACE1 was highlighted as an early 
diagnostic biomarker in AD patients. 
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